Development and validation of a HPTLC method for analysis of Sunitinib malate

Detalhes bibliográficos
Autor(a) principal: Hajmalek, Monireh
Data de Publicação: 2016
Outros Autores: Goudarzi, Masoumeh, Ghaffari, Solmaz, Attar, Hossein, Mazlaghan, Mehrnoosh Ghanbari
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/128375
Resumo: A simple high performance thin layer chromatography (HPTLC) has been developed and validated for determination of sunitinib malate and possible impurities. The samples were applied in forms of bands on an aluminum TLC plate pre-coated with silica gel and were separated using dichloromethane: methanol: toluene: ammonia solution as the mobile phase. Sunitinib malate was thoroughly separated from impurities including E-isomer, sunitinib N-oxide and impurity B with a retention factor (RF) of 0.35±0.02. Quantitative analysis of sunitinib was carried out using a mobile phase consisting of dichloromethane:methanol:ammonia solution, RF value was 0.53±0.02 for Z isomer. Detection was performed densitometrically in absorbance mode at 430 nm. This method was found to produce sharp, symmetrical, and well resolved peaks. Linear relationship with the coefficients of determination >; 0.99 was achieved over the concentration range of 27.34 to 437.5 ng/spot. This method provides robust, replicable and accurate results with acceptable sensitivity.
id USP-31_98c15e69364842c26abbd270e3f378c0
oai_identifier_str oai:revistas.usp.br:article/128375
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Development and validation of a HPTLC method for analysis of Sunitinib malate A simple high performance thin layer chromatography (HPTLC) has been developed and validated for determination of sunitinib malate and possible impurities. The samples were applied in forms of bands on an aluminum TLC plate pre-coated with silica gel and were separated using dichloromethane: methanol: toluene: ammonia solution as the mobile phase. Sunitinib malate was thoroughly separated from impurities including E-isomer, sunitinib N-oxide and impurity B with a retention factor (RF) of 0.35±0.02. Quantitative analysis of sunitinib was carried out using a mobile phase consisting of dichloromethane:methanol:ammonia solution, RF value was 0.53±0.02 for Z isomer. Detection was performed densitometrically in absorbance mode at 430 nm. This method was found to produce sharp, symmetrical, and well resolved peaks. Linear relationship with the coefficients of determination >; 0.99 was achieved over the concentration range of 27.34 to 437.5 ng/spot. This method provides robust, replicable and accurate results with acceptable sensitivity. Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2016-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/12837510.1590/s1984-82502016000400003Brazilian Journal of Pharmaceutical Sciences; Vol. 52 Núm. 4 (2016); 595-601Brazilian Journal of Pharmaceutical Sciences; v. 52 n. 4 (2016); 595-601Brazilian Journal of Pharmaceutical Sciences; Vol. 52 No. 4 (2016); 595-6012175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/128375/125246Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessHajmalek, MonirehGoudarzi, MasoumehGhaffari, SolmazAttar, HosseinMazlaghan, Mehrnoosh Ghanbari2017-03-16T18:09:44Zoai:revistas.usp.br:article/128375Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2017-03-16T18:09:44Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Development and validation of a HPTLC method for analysis of Sunitinib malate
title Development and validation of a HPTLC method for analysis of Sunitinib malate
spellingShingle Development and validation of a HPTLC method for analysis of Sunitinib malate
Hajmalek, Monireh
title_short Development and validation of a HPTLC method for analysis of Sunitinib malate
title_full Development and validation of a HPTLC method for analysis of Sunitinib malate
title_fullStr Development and validation of a HPTLC method for analysis of Sunitinib malate
title_full_unstemmed Development and validation of a HPTLC method for analysis of Sunitinib malate
title_sort Development and validation of a HPTLC method for analysis of Sunitinib malate
author Hajmalek, Monireh
author_facet Hajmalek, Monireh
Goudarzi, Masoumeh
Ghaffari, Solmaz
Attar, Hossein
Mazlaghan, Mehrnoosh Ghanbari
author_role author
author2 Goudarzi, Masoumeh
Ghaffari, Solmaz
Attar, Hossein
Mazlaghan, Mehrnoosh Ghanbari
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Hajmalek, Monireh
Goudarzi, Masoumeh
Ghaffari, Solmaz
Attar, Hossein
Mazlaghan, Mehrnoosh Ghanbari
description A simple high performance thin layer chromatography (HPTLC) has been developed and validated for determination of sunitinib malate and possible impurities. The samples were applied in forms of bands on an aluminum TLC plate pre-coated with silica gel and were separated using dichloromethane: methanol: toluene: ammonia solution as the mobile phase. Sunitinib malate was thoroughly separated from impurities including E-isomer, sunitinib N-oxide and impurity B with a retention factor (RF) of 0.35±0.02. Quantitative analysis of sunitinib was carried out using a mobile phase consisting of dichloromethane:methanol:ammonia solution, RF value was 0.53±0.02 for Z isomer. Detection was performed densitometrically in absorbance mode at 430 nm. This method was found to produce sharp, symmetrical, and well resolved peaks. Linear relationship with the coefficients of determination >; 0.99 was achieved over the concentration range of 27.34 to 437.5 ng/spot. This method provides robust, replicable and accurate results with acceptable sensitivity.
publishDate 2016
dc.date.none.fl_str_mv 2016-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/128375
10.1590/s1984-82502016000400003
url https://www.revistas.usp.br/bjps/article/view/128375
identifier_str_mv 10.1590/s1984-82502016000400003
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/128375/125246
dc.rights.driver.fl_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 52 Núm. 4 (2016); 595-601
Brazilian Journal of Pharmaceutical Sciences; v. 52 n. 4 (2016); 595-601
Brazilian Journal of Pharmaceutical Sciences; Vol. 52 No. 4 (2016); 595-601
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222912855146496